Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000407599 | SCV000344801 | uncertain significance | not provided | 2017-12-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000524954 | SCV000649966 | likely benign | Autosomal recessive limb-girdle muscular dystrophy type 2O; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 | 2024-01-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000763938 | SCV000894883 | uncertain significance | Muscle eye brain disease; Autosomal recessive limb-girdle muscular dystrophy type 2O; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3; Retinitis pigmentosa 76 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000407599 | SCV002005009 | uncertain significance | not provided | 2020-03-27 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Athena Diagnostics | RCV000407599 | SCV002771137 | uncertain significance | not provided | 2022-02-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002518127 | SCV003738465 | uncertain significance | Inborn genetic diseases | 2022-02-17 | criteria provided, single submitter | clinical testing | The c.269G>A (p.R90H) alteration is located in exon 4 (coding exon 3) of the POMGNT1 gene. This alteration results from a G to A substitution at nucleotide position 269, causing the arginine (R) at amino acid position 90 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001275757 | SCV001461207 | uncertain significance | Muscle eye brain disease | 2020-09-16 | no assertion criteria provided | clinical testing |